Preferred Label : Roflumilast;
NCIt synonyms : 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;
NCIt definition : An orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4),
with anti-inflammatory and potential antineoplastic activities. Upon administration,
roflumilast and its active metabolite roflumilast N-oxide selectively and competitively
bind to and inhibit PDE4, which leads to an increase of both intracellular levels
of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. cAMP prevents
phosphorylation of spleen tyrosine kinase (SYK) and abrogates activation of the PI3K/AKT/mTOR
signaling pathway, which may result in the induction of apoptosis. PDE4, a member
of the PDE superfamily that hydrolyses cAMP and 3',5'-cyclic guanosine monophosphate
(cGMP) to their inactive 5' monophosphates, is upregulated in a variety of cancers
and may contribute to chemoresistance; it also plays a key role in inflammation, especially
in inflammatory airway diseases.;
UNII : 0P6C6ZOP5U;
InChIKey : MNDBXUUTURYVHR-UHFFFAOYSA-N;
CAS number : 162401-32-3;
Drug name : Daliresp;
Molecule name : BYK20869; B9302-107; BY217;
Chemical formula : C17H14Cl2F2N2O3;
Origin ID : C76890;
UMLS CUI : C0965618;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
